AbbVie reported first quarter 2026 revenue of $15.002 billion, a 12.4% year-over-year increase that surpassed analyst expectations of $14.78 billion. Adjusted diluted EPS came in at $2.65, missing the $2.69 consensus estimate but growing 7.7% from the prior year. The company raised its full-year 2026 adjusted EPS guidance.
Key Highlights
- The key immunology portfolio grew revenues by 16.4% to $7.29 billion, driven by combined Skyrizi and Rinvoq sales of $6.602 billion, which exceeded the $6.5 billion analyst estimate.
- Skyrizi global net revenues surged 30.9% to $4.483 billion, while Rinvoq global net revenues increased 23.3% to $2.119 billion, successfully offsetting the ongoing decline in Humira sales, which were down 38.6% to $688 million.
- The Neuroscience portfolio also demonstrated strong performance, with revenues growing 26.0% to $2.875 billion, led by Botox Therapeutic ($1.009 billion) and Vraylar ($905 million).
- AbbVie raised its full-year 2026 adjusted diluted EPS guidance to a new range of $14.08 - $14.28, up from the previous range of $13.96 - $14.16.